Pancreatic Cancer News

CancerConnect pancreatic cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of pancreatic cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of pancreatic cancer treatment and survivorship.

Share

Pancreatic Cancer News


Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing... Continue Reading

Immunotherapy for Pancreatic Cancer Boosts Survival by More Than 75% in Mice; Trials in Humans Coming (March 1, 2016)

A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy — even when used without chemotherapy or radiation — can boost survival... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (February 11, 2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The... Continue Reading

MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer (January 11, 2016)

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, announces that it has received notice from the U.S. Food and Drug Administration (FDA) authorizing the initiation... Continue Reading

November is National Pancreatic Cancer Awareness Month (November 17, 2015)

Copyright © 2016 CancerConnect. All Rights Reserved. Read More →

Onivyde Approved for Pancreatic Cancer (November 3, 2015)

The United States Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer. The... Continue Reading

What Can Your Gut Tell You About Cancer? (October 16, 2015)

Learn to identify and manage gastrointestinal issues to maintain overall health. By Mia James At the very least, gastro­intestinal (GI) symp­toms are bother­some and sometimes embarrassing. No one feels... Continue Reading

Protein Circulating in Blood Could Be Key to Early Diagnosis of Pancreatic Cancer (August 6, 2015)

Research suggests a promising new way to screen for and detect early pancreatic cancer. Certain proteins that circulate in the blood may help identify patients with this disease, for which there’s currently... Continue Reading

“Boosted” Radiation Dose May Make Some Pancreatic Cancers Resectable (June 24, 2015)

Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically... Continue Reading

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer (November 26, 2014)

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer,... Continue Reading

More Pancreatic Cancer News

Latest Pancreatic Cancer News By Stage


Screening and Prevention

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced... Continue Reading

Protein Circulating in Blood Could Be Key to Early Diagnosis of Pancreatic Cancer (August 6, 2015)

Research suggests a promising new way to screen for and detect early pancreatic cancer. Certain proteins that circulate in the blood may help identify patients with this disease, for which there’s currently no reliable screening. These findings were... Continue Reading

National Pancreatic Cancer Awareness Month on CancerConnect (November 3, 2014)

As the month of November brings pancreatic cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated pancreatic... Continue Reading

Aspirin Reduces Risk of Pancreatic Cancer (July 1, 2014)

The results of a recent study suggest that regular aspirin use reduces the risk of pancreatic cancer by half.  Clinical studies have also found that regular aspirin use can reduce the risk for colon, esophageal, lung and prostate cancers, as well as... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

More Screening and Prevention

Stages I-III

MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer (January 11, 2016)

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, announces that it has received notice from the U.S. Food and Drug Administration (FDA) authorizing the initiation a Phase I clinical trial with HuMab-5B1 as a therapeutic... Continue Reading

“Boosted” Radiation Dose May Make Some Pancreatic Cancers Resectable (June 24, 2015)

Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more... Continue Reading

Jakafi Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation (June 2, 2014)

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with Jakafi® (ruxolitinib) plus capecitabine improved overall survival and progression-free survival in metastatic pancreatic... Continue Reading

Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET) (June 2, 2011)

The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are an uncommon type of cancer that develops in the hormone-producing cells... Continue Reading

Afinitor Approved for Pancreatic Neuroendocrine Tumors (May 10, 2011)

The US Food and Drug Administration has approved Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are a relatively uncommon type of cancer that develops in the hormone-producing... Continue Reading

More Stages I and III

Stage IV

MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer (January 11, 2016)

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, announces that it has received notice from the U.S. Food and Drug Administration (FDA) authorizing the initiation a Phase I clinical trial with HuMab-5B1 as a therapeutic... Continue Reading

Onivyde Approved for Pancreatic Cancer (November 3, 2015)

The United States Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer. The approval is indicated for patients with... Continue Reading

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer (November 26, 2014)

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer, based on data from the phase III NAPOLI-1 study... Continue Reading

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer (October 7, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer (September 23, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

More Stage IV

Recurrent

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer (November 26, 2014)

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer, based on data from the phase III NAPOLI-1 study... Continue Reading

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer (October 7, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer (September 23, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (July 10, 2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine).... Continue Reading

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy (July 1, 2014)

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer... Continue Reading

More Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS